Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MMMT
MCID: CRC021
MIFTS: 62

Carcinosarcoma (MMMT)

Categories: Bone diseases, Cancer diseases, Rare diseases, Reproductive diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Carcinosarcoma

About this section

MalaCards integrated aliases for Carcinosarcoma:

Name: Carcinosarcoma 12 53 55 44 15
Malignant Mixed Mullerian Tumor 12 53
Mixed Tumor, Mullerian 53 44
Mmmt 12 53
Malignant Mixed Mesodermal Tumor 12
Malignant Mixed M�llerian Tumor 76
Mixed Mesodermal Tumor 12
Mixed Tumor, Mesodermal 44
Mesodermal Mixed Tumor 12
Mullerian Mixed Tumor 12
Mixed M�llerian Tumor 76
Mixed Mullerian Tumor 53
Mixed Tumor Mullerian 55

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Bone diseases Reproductive diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4236
SNOMED-CT 68 63264007 84427001
Sources

Summaries for Carcinosarcoma

About this section
NIH Rare Diseases : 53 A malignant mixed müllerian tumor (MMMT), also called a carcinosarcoma, is a type of cancer that contains two types of cancer cells - carcinoma and sarcoma cells. These tumors usually develop in tissues of the female genital tract and are associated with a poor outcome. The majority of these tumors arise in the uterus, though they can also occur in the ovaries, fallopian tubes, and cervix. Very rarely, MMMTs can develop in the female peritoneum (lining of the abdominal wall).

MalaCards based summary : Carcinosarcoma, also known as malignant mixed mullerian tumor, is related to cervical carcinosarcoma and uterine carcinosarcoma. An important gene associated with Carcinosarcoma is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include uterus, ovary and cervix, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A mixed cell type cancer that has material basis in carcinomatous (epithelial tissue) and sarcomatous (connective tissue) components.

Wikipedia : 76 A malignant mixed Müllerian tumor, also known as malignant mixed mesodermal tumor, MMMT and ... more...

Sources

Related Diseases for Carcinosarcoma

About this section

Diseases related to Carcinosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 479)
# Related Disease Score Top Affiliating Genes
1 cervical carcinosarcoma 33.4 MME PGR TP53
2 uterine carcinosarcoma 32.5 CTNNB1 ERBB2 HRAS KIT MME PGR
3 adenosarcoma 31.7 DES KIT MME PGR TP53
4 adenomyoma 31.3 CTNNB1 KRT7 MME MUC1
5 uterine sarcoma 30.2 DES KIT MME
6 pleomorphic adenoma 30.2 ACTC1 ERBB2 MUC1 TP53 VIM
7 papillary serous adenocarcinoma 30.2 KRT7 PGR TP53
8 rhabdomyosarcoma 30.2 ACTC1 DES TP53 VIM
9 pulmonary blastoma 30.1 DES KRAS TP53
10 breast metaplastic carcinoma 30.1 ERBB2 PGR
11 squamous cell carcinoma 30.1 CTNNB1 ERBB2 HRAS MUC1 PIK3CA PTEN
12 liposarcoma 30.0 DES TP53 VIM
13 thymoma 30.0 HRAS KIT TP53
14 sarcoma 30.0 CTNNB1 HRAS KIT KRAS PIK3CA TP53
15 teratoma 29.9 ACTC1 KIT KRT7 TP53
16 spiradenoma 29.9 ACTC1 KRT7 TP53 VIM
17 uterine corpus serous adenocarcinoma 29.9 ERBB2 PIK3CA TP53
18 spindle cell thymoma 29.9 DES MUC1
19 papilloma 29.9 KRT7 PTEN TP53
20 basal cell carcinoma 29.8 CTNNB1 KRT7 MME PTEN TP53
21 adenofibroma 29.8 ACTC1 MME MUC1 VIM
22 leiomyosarcoma 29.8 ACTC1 DES KIT PGR TP53 VIM
23 epithelial-myoepithelial carcinoma 29.8 HRAS KRT7 TP53
24 ovarian cancer 1 29.8 ERBB2 KRAS KRT7 PIK3CA TP53
25 dermoid cyst 29.8 KIT KRT7 MUC1 PGR VIM
26 pleomorphic liposarcoma 29.8 DES MUC1 VIM
27 fallopian tube carcinoma 29.8 ERBB2 PGR TP53
28 mucoepidermoid carcinoma 29.8 ERBB2 KRT7 MUC1
29 in situ carcinoma 29.8 ERBB2 PGR TP53
30 tubular adenocarcinoma 29.7 ERBB2 MUC1 PGR
31 undifferentiated pleomorphic sarcoma 29.7 KIT KRAS PIK3CA
32 spindle cell carcinoma 29.7 ACTC1 DES KRT7 MUC1 PGR VIM
33 spindle cell sarcoma 29.7 ACTC1 DES KRT7 MUC1 VIM
34 angiosarcoma 29.7 KIT KRAS MUC1 VIM
35 fibrous histiocytoma 29.7 ACTC1 DES VIM
36 mixed cell type cancer 29.6 ERBB2 HRAS KIT KRT7 MME PGR
37 merkel cell carcinoma 29.6 KIT KRT7 MUC1 TP53
38 gliosarcoma 29.6 ACTC1 PTEN TP53 VIM
39 ovary adenocarcinoma 29.6 ERBB2 HRAS KRAS KRT7 PIK3CA TP53
40 malignant fibroxanthoma 29.5 ACTC1 DES MUC1 VIM
41 mucinous adenocarcinoma 29.5 KRAS KRT7 MUC1
42 serous cystadenocarcinoma 29.5 ERBB2 HRAS PGR PIK3CA TP53
43 small cell cancer of the lung 29.5 KIT KRT7 PIK3CA PTEN TP53
44 chordoma 29.5 DES KRT7 MUC1 PTEN VIM
45 cystadenocarcinoma 29.4 ERBB2 HRAS KRT7 MUC1 PGR PIK3CA
46 adenocarcinoma 29.3 CTNNB1 ERBB2 HRAS KIT KRAS MUC1
47 inflammatory myofibroblastic tumor 29.3 ACTC1 DES KIT TP53 VIM
48 endometrial stromal sarcoma 29.3 ACTC1 DES KIT MME PGR TP53
49 papillary adenocarcinoma 29.3 ERBB2 KRT7 MUC1 PGR TP53 VIM
50 adenosquamous carcinoma 29.3 KIT KRAS KRT7 MUC1 PIK3CA TP53

Graphical network of the top 20 diseases related to Carcinosarcoma:



Diseases related to Carcinosarcoma
Sources

Symptoms & Phenotypes for Carcinosarcoma

About this section

GenomeRNAi Phenotypes related to Carcinosarcoma according to GeneCards Suite gene sharing:

26 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.3 HRAS KRAS MUC1 PIK3CA
2 Decreased viability GR00106-A-0 10.3 KRAS
3 Decreased viability GR00221-A-1 10.3 HRAS KRAS PIK3CA
4 Decreased viability GR00221-A-2 10.3 HRAS KRAS PIK3CA
5 Decreased viability GR00221-A-3 10.3 HRAS
6 Decreased viability GR00221-A-4 10.3 PIK3CA
7 Decreased viability GR00301-A 10.3 KRAS
8 Decreased viability GR00381-A-1 10.3 KRAS
9 Decreased viability GR00402-S-2 10.3 HRAS KRAS MUC1 PIK3CA
10 Decreased viability in esophageal squamous lineage GR00235-A 10 CTNNB1 DES ERBB2 HRAS KIT KRAS
11 Decreased cell migration GR00055-A-1 9.88 CTNNB1 HRAS KRAS MUC1 PIK3CA VIM
12 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.85 CTNNB1 ERBB2 HRAS MUC1 PTEN VIM
13 Increased cell death HMECs cells GR00103-A-0 9.55 CTNNB1 PGR PIK3CA PTEN TP53
14 Increased cell migration GR00055-A-3 9.26 CTNNB1 HRAS KRAS PIK3CA
15 Reduced mammosphere formation GR00396-S 9.1 DES HRAS KRAS KRT7 PTEN VIM

MGI Mouse Phenotypes related to Carcinosarcoma:

46 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.4 ACTC1 CTNNB1 DES ERBB2 HRAS KIT
2 cardiovascular system MP:0005385 10.38 ACTC1 CTNNB1 DES ERBB2 HRAS KIT
3 cellular MP:0005384 10.38 ACTC1 CTNNB1 DES ERBB2 KIT KRAS
4 behavior/neurological MP:0005386 10.35 CTNNB1 DES ERBB2 HRAS KIT KRAS
5 mortality/aging MP:0010768 10.29 ACTC1 CTNNB1 DES ERBB2 HRAS KIT
6 integument MP:0010771 10.24 CTNNB1 ERBB2 HRAS KIT KRAS MME
7 muscle MP:0005369 10.24 ACTC1 CTNNB1 DES ERBB2 KIT KRAS
8 embryo MP:0005380 10.23 CTNNB1 ERBB2 KIT KRAS PGR PIK3CA
9 endocrine/exocrine gland MP:0005379 10.22 CTNNB1 ERBB2 HRAS KIT KRAS PGR
10 immune system MP:0005387 10.2 CTNNB1 KIT KRAS MME PGR PIK3CA
11 digestive/alimentary MP:0005381 10.13 CTNNB1 ERBB2 HRAS KIT KRAS PTEN
12 neoplasm MP:0002006 10.13 CTNNB1 ERBB2 HRAS KIT KRAS PGR
13 nervous system MP:0003631 10.11 CTNNB1 ERBB2 HRAS KIT KRAS PIK3CA
14 craniofacial MP:0005382 10.07 CTNNB1 ERBB2 HRAS KIT KRAS TP53
15 limbs/digits/tail MP:0005371 10.07 CTNNB1 ERBB2 KIT KRAS PGR PTEN
16 normal MP:0002873 10.06 ACTC1 CTNNB1 ERBB2 HRAS KIT KRAS
17 no phenotypic analysis MP:0003012 9.98 CTNNB1 HRAS KIT KRAS PGR PIK3CA
18 reproductive system MP:0005389 9.91 CTNNB1 ERBB2 KIT KRAS PGR PIK3CA
19 renal/urinary system MP:0005367 9.87 CTNNB1 HRAS KIT KRAS KRT7 PTEN
20 pigmentation MP:0001186 9.77 CTNNB1 KIT KRAS PTEN TP53
21 respiratory system MP:0005388 9.76 CTNNB1 ERBB2 HRAS KIT KRAS PTEN
22 skeleton MP:0005390 9.61 CTNNB1 ERBB2 HRAS KIT KRAS PGR
23 vision/eye MP:0005391 9.17 CTNNB1 KIT KRAS PIK3CA PTEN TP53
Sources

Drugs & Therapeutics for Carcinosarcoma

About this section

Drugs for Carcinosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 117)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
2
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
3
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
4
Lenograstim Approved, Investigational Phase 3,Phase 1 135968-09-1
5
Mechlorethamine Approved, Investigational Phase 3,Phase 2 51-75-2 4033
6
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
7
Mesna Approved, Investigational Phase 3,Phase 2 3375-50-6 598
8
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
9
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
10
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
11
Topotecan Approved, Investigational Phase 2, Phase 3 123948-87-8, 119413-54-6 60700
12
Niraparib Approved, Investigational Phase 2, Phase 3 1038915-60-4 24958200
13
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
14
Cyproheptadine Approved Phase 3 129-03-3 2913
15
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
16 Alkylating Agents Phase 3,Phase 2
17 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
18 Antineoplastic Agents, Alkylating Phase 3,Phase 2
19 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
20 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1,Not Applicable
21
Isophosphamide mustard Phase 3,Phase 2 0
22 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
23 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
24 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
25 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
26 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
27 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3,Phase 1
28 Serotonin Agents Phase 3
29 Anti-Allergic Agents Phase 3
30 Serotonin Antagonists Phase 3
31 Histamine H1 Antagonists Phase 3
32
Histamine Phosphate Phase 3 51-74-1 65513
33 Antipruritics Phase 3
34 Neurotransmitter Agents Phase 3
35 Dermatologic Agents Phase 3
36 Histamine Antagonists Phase 3
37 Gastrointestinal Agents Phase 3
38
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
39
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
40
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
41
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
42
Docetaxel Approved, Investigational Phase 2,Phase 1 114977-28-5 148124
43
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
44
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
45
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
46
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
47
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
48
Everolimus Approved Phase 2 159351-69-6 6442177
49
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
50
Olaparib Approved Phase 2 763113-22-0 23725625

Interventional clinical trials:

(show top 50) (show all 81)
# Name Status NCT ID Phase Drugs
1 Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus Completed NCT00003128 Phase 3 ifosfamide;paclitaxel
2 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus Completed NCT00002546 Phase 3 cisplatin;ifosfamide
3 Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus Completed NCT00002459 Phase 3
4 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
5 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
6 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
7 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Active, not recruiting NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
8 Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib Not yet recruiting NCT03651206 Phase 2, Phase 3 Niraparib;Chemotherapy Drugs
9 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
10 Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble - Unknown status NCT02203760 Phase 2 Pazopanib plus Gemcitabine;Pazopanib
11 Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Unknown status NCT00838656 Phase 2 carboplatin;gemcitabine hydrochloride;paclitaxel
12 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
13 Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Completed NCT00687687 Phase 2 paclitaxel;carboplatin;BSI-201 (Iniparib)
14 Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2 Thalidomide
15 Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus Completed NCT00502203 Phase 2 Carboplatin;Paclitaxel
16 Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus Completed NCT00476086 Phase 2 Gemcitabine;Oxaliplatin
17 Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01247571 Phase 2 Pazopanib Hydrochloride
18 Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01168232 Phase 2 Ixabepilone
19 Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00114218 Phase 2 Gemcitabine Hydrochloride;Docetaxel
20 Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00075400 Phase 2 imatinib mesylate
21 Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer Completed NCT00238121 Phase 2 sorafenib tosylate
22 Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer Completed NCT00112489 Phase 2 carboplatin;paclitaxel
23 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2 PegLiposomal Doxorubicin;Carboplatin
24 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed NCT00390234 Phase 2 ziv-aflibercept
25 Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
26 Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer Completed NCT00511992 Phase 2 Avastin;Paclitaxel;Cisplatin
27 Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed Mesodermal Tumors of the Uterus Completed NCT00231842 Phase 2 Ifosfamide;Cisplatin
28 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2 Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
29 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
30 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
31 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
32 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
33 Chemotherapy in Treating Patients With Sarcoma of the Uterus Completed NCT00005643 Phase 2 pegylated liposomal doxorubicin hydrochloride
34 Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract Completed NCT00003334 Phase 2 paclitaxel;pegylated liposomal doxorubicin hydrochloride
35 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
36 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
37 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
38 Thalidomide in Treating Patients With Gynecologic Sarcomas Completed NCT00006005 Phase 2 thalidomide
39 Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer Completed NCT00032162 Phase 1, Phase 2 carboplatin;pegylated liposomal doxorubicin hydrochloride
40 Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors Completed NCT00520013 Phase 2 bevacizumab;erlotinib;paclitaxel;carboplatin
41 A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer Recruiting NCT03015129 Phase 2 Durvalumab;Tremelimumab
42 Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel? Recruiting NCT03570437 Phase 2 Paclitaxel;Cediranib;Olaparib
43 Vorinostat (SAHA) in Uterine Sarcoma Recruiting NCT03509207 Phase 2 Vorinostat Oral Capsule
44 European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer Recruiting NCT03783949 Phase 2 Ganetespib;Niraparib;Carboplatin;Paclitaxel;Gemcitabine
45 A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers Recruiting NCT02923934 Phase 2 Ipilimumab;Nivolumab
46 Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Recruiting NCT02874430 Phase 2 Metformin Hydrochloride;Doxycycline
47 Phase II Study of Intrauterine Device (IUD) Alone or in Combination With Everolimus in Endometrial Cancer Recruiting NCT02397083 Phase 2 Everolimus
48 A Study of Nivolumab in Selected Uterine Cancer Patients Recruiting NCT03241745 Phase 2 Nivolumab
49 Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Osteosarcoma, or Pancreatic Ductal Adenocarcinoma Recruiting NCT03610490 Phase 2 Cyclophosphamide;Fludarabine
50 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2

Search NIH Clinical Center for Carcinosarcoma

Cochrane evidence based reviews: carcinosarcoma

Sources

Genetic Tests for Carcinosarcoma

About this section
Sources

Anatomical Context for Carcinosarcoma

About this section

MalaCards organs/tissues related to Carcinosarcoma:

41
Uterus, Ovary, Cervix, Breast, Lung, Bone, Prostate
Sources

Publications for Carcinosarcoma

About this section

Articles related to Carcinosarcoma:

(show top 50) (show all 1139)
# Title Authors Year
1
Gas Gangrene of Malignant Mixed Mullerian Tumor of Ovary Caused by Clostridium perfringens. ( 29685470 )
2018
2
Lymphadenectomy and Adjuvant Therapy Improve Survival with Uterine Carcinosarcoma: A Large Retrospective Cohort Study. ( 29791913 )
2018
3
Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma. ( 29971677 )
2018
4
Fluorodeoxyglucose Positron Emission Tomography-computed Tomography Evaluation of an Interesting Case of Uterine Carcinosarcoma with Isolated Appendicular Skeletal Metastases. ( 29643680 )
2018
5
Trends of uterine carcinosarcoma in the United States. ( 29400015 )
2018
6
Tumor Mutational Burden Guides Therapy in a Treatment Refractory<i>POLE-</i>Mutant Uterine Carcinosarcoma. ( 29386312 )
2018
7
The Association of an Elevated Thrombocyte Count with Clinicopathological Prognostic Factors and Survival in Patients with Uterine Carcinosarcoma. ( 29629727 )
2018
8
Esophageal carcinosarcoma comprised of minimally invasive squamous cell carcinoma and undifferentiated pleomorphic sarcoma: A collision cancer? ( 29934989 )
2018
9
Diagnostic accuracy of 3.0T diffusion-weighted MRI for patients with uterine carcinosarcoma: Assessment of tumor extent and lymphatic metastasis. ( 29437265 )
2018
10
Insulin-like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma. ( 29455465 )
2018
11
Prognostic Significance of omental Disease and the Role of Omental Sampling in Patients With Uterine Carcinosarcoma. ( 29303931 )
2018
12
Synchronous endometrial adenocarcinoma and carcinosarcoma in endometrial polyp. ( 29854405 )
2018
13
Carcinosarcoma ex Pleomorphic Adenoma of the Submandibular Gland in a 64-Year-Old Man: A Case Report. ( 29540647 )
2018
14
Significance of venous thromboembolism in women with uterine carcinosarcoma. ( 29248197 )
2018
15
Usefulness of ascites cytology for the evaluation of chemotherapy response in ovarian carcinosarcoma. ( 29488261 )
2018
16
Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature. ( 29426293 )
2018
17
Impact of radiotherapy modalities on outcomes in the adjuvant management of uterine carcinosarcoma: A National Cancer Database analysis. ( 29097136 )
2018
18
Carcinosarcoma of Breast Mimicking Breast Abscess. ( 30288006 )
2018
19
Odontogenic carcinosarcoma: A systematic review. ( 30220320 )
2018
20
Inversion of the Uterus Combined with Endometrial Carcinosarcoma. ( 30246728 )
2018
21
A Case of Primary Cutaneous Basal Cell Carcinosarcoma. ( 30283313 )
2018
22
Primary Intracranial Manifestation of a Carcinosarcoma. ( 30283584 )
2018
23
Mullerian carcinosarcoma in the colon of a patient with history of endometrial carcinoma: A case report and insight into possible pathogenesis. ( 30294656 )
2018
24
Radiation-Induced Uterine Carcinosarcoma after Concurrent Chemoradiotherapy for Cervical Squamous Cell Carcinoma. ( 30308682 )
2018
25
Metastatic esophageal carcinosarcoma comprising neuroendocrine carcinoma, squamous cell carcinoma, and sarcoma: A case report. ( 30313107 )
2018
26
Primary peritoneal carcinosarcoma arising from the Douglas pouch: A case report. ( 30345041 )
2018
27
Multiple Myeloma Masquerading as Ovarian Carcinosarcoma Metastases: A Case Report and Review of the Approach to Multiple Myeloma Screening and Diagnosis. ( 30345126 )
2018
28
Uterine carcinosarcoma (malignant mixed Müllerian tumor): case report in a goat and literature review. ( 30345891 )
2018
29
Molecular classification and subtype-specific drug sensitivity research of uterine carcinosarcoma under multi-omics framework. ( 30359167 )
2018
30
Prognostic factors impacting survival in early stage uterine carcinosarcoma. ( 30414738 )
2018
31
Ultrasonographic Findings of Uterine Carcinosarcoma. ( 30504724 )
2018
32
Carcinosarcoma of Tongue with Predominant Osteosarcomatous Component. ( 30538400 )
2018
33
Diagnostic Value of 18F-FDG PET/CT and MRI in the Preoperative Evaluation of Uterine Carcinosarcoma. ( 30538776 )
2018
34
Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report. ( 30541518 )
2018
35
Odontogenic carcinosarcoma: morphologic and immunohistochemical description of a case. ( 30554629 )
2018
36
Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment. ( 29143144 )
2018
37
Primary Carcinosarcoma of the Vagina Associated With Differentiated Squamous Intraepithelial Neoplasia in a Patient With Complete Uterine Prolapse: Case Report and Review of the Literature. ( 29207889 )
2018
38
Fine-Needle Aspiration Cytology of Carcinosarcoma in the Salivary Gland: An Extremely Rare Case Report. ( 29281871 )
2018
39
The gastric carcinosarcoma with severe venous invasion: a case report. ( 29380091 )
2018
40
Primary cutaneous carcinosarcoma developing after chronic C-arm radiation exposure. ( 29387761 )
2018
41
Carcinosarcoma mimicking a feline injection-site sarcoma in a cat. ( 29420837 )
2018
42
Preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal carcinosarcoma: a case report and review of the literature. ( 29455418 )
2018
43
Primary carcinosarcoma of the liver: imaging features and clinical findings in six cases and a review of the literature. ( 29482629 )
2018
44
Giant Pendulous Carcinosarcoma - Squamous Cell Carcinoma-Type - of the Leg - A Case Report and Review of the Literature. ( 29484002 )
2018
45
Metaplastic carcinoma of the breast with mesenchymal differentiation (carcinosarcoma). A unique presentation of an aggressive malignancy and literature review. ( 29504519 )
2018
46
A Case of Early Stage Bladder Carcinosarcoma in Late Recurrence of Urothelial Carcinoma after Transurethral Resection. ( 29568660 )
2018
47
Outcomes of carcinosarcoma in a tertiary care institution in India. ( 29600231 )
2018
48
Morphological features of doxorubicin-resistant Walker 256 carcinosarcoma and response of mast cells. ( 29600974 )
2018
49
Coexistence of BRAF V600E and TERT Promoter Mutations in Low-grade Serous Carcinoma of Ovary Recurring as Carcinosarcoma in a Lymph Node: Report of a Case. ( 29620581 )
2018
50
Primary Cutaneous Carcinosarcoma: A cutaneous neoplasm with an exceptional presentation. ( 29666695 )
2018
Sources

Variations for Carcinosarcoma

About this section

Cosmic variations for Carcinosarcoma:

9 (show top 50) (show all 122)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM10663 TP53 ovary,NS,carcinoma,adenocarcinoma c.916C>T p.R306* 17:7673704-7673704 4
2 COSM11066 TP53 ovary,NS,carcinoma,adenocarcinoma c.578A>T p.H193L 17:7674953-7674953 4
3 COSM10738 TP53 ovary,NS,carcinoma,adenocarcinoma c.542G>A p.R181H 17:7675070-7675070 4
4 COSM11148 TP53 ovary,NS,carcinoma,adenocarcinoma c.476C>T p.A159V 17:7675136-7675136 4
5 COSM11582 TP53 ovary,NS,carcinoma,adenocarcinoma c.395A>G p.K132R 17:7675217-7675217 4
6 COSM6904336 TNFAIP3 ovary,NS,carcinoma,adenocarcinoma c.940G>A p.V314I 6:137877210-137877210 4
7 COSM14135 SMAD4 ovary,NS,carcinoma,adenocarcinoma c.1051G>C p.D351H 18:51065518-51065518 4
8 COSM6904335 SMAD2 ovary,NS,carcinoma,adenocarcinoma c.785-1G>C p.? 18:47848688-47848688 4
9 COSM6904334 RET ovary,NS,carcinoma,adenocarcinoma c.3253A>G p.T1085A 10:43128177-43128177 4
10 COSM6904339 PTCH1 ovary,NS,carcinoma,adenocarcinoma c.3074G>A p.R1025H 9:95458107-95458107 4
11 COSM760 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.1624G>A p.E542K 3:179218294-179218294 4
12 COSM770 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.2725T>C p.F909L 3:179230062-179230062 4
13 COSM21446 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.3012G>T p.M1004I 3:179234169-179234169 4
14 COSM746 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.263G>A p.R88Q 3:179199088-179199088 4
15 COSM94978 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.1034A>T p.N345I 3:179203764-179203764 4
16 COSM766 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.1636C>A p.Q546K 3:179218306-179218306 4
17 COSM564 NRAS ovary,NS,carcinoma,adenocarcinoma c.35G>A p.G12D 1:114716126-114716126 4
18 COSM580 NRAS ovary,NS,carcinoma,adenocarcinoma c.181C>A p.Q61K 1:114713909-114713909 4
19 COSM522 KRAS ovary,NS,carcinoma,adenocarcinoma c.35G>C p.G12A 12:25245350-25245350 4
20 COSM14065 ERBB2 ovary,NS,carcinoma,adenocarcinoma c.2524G>A p.V842I 17:39725079-39725079 4
21 COSM22992 EGFR ovary,NS,carcinoma,adenocarcinoma c.2161G>A p.G721S 7:55174020-55174020 4
22 COSM53264 EGFR ovary,NS,carcinoma,adenocarcinoma c.2174C>T p.T725M 7:55174033-55174033 4
23 COSM6224 EGFR ovary,NS,carcinoma,adenocarcinoma c.2573T>G p.L858R 7:55191822-55191822 4
24 COSM53230 EGFR ovary,NS,carcinoma,adenocarcinoma c.2597A>G p.E866G 7:55191846-55191846 4
25 COSM28511 EGFR ovary,NS,carcinoma,adenocarcinoma c.2108T>C p.L703P 7:55173967-55173967 4
26 COSM53225 EGFR ovary,NS,carcinoma,adenocarcinoma c.2112G>A p.L704L 7:55173971-55173971 4
27 COSM53232 EGFR ovary,NS,carcinoma,adenocarcinoma c.2122A>G p.K708E 7:55173981-55173981 4
28 COSM53226 EGFR ovary,NS,carcinoma,adenocarcinoma c.2099A>G p.N700S 7:55173958-55173958 4
29 COSM53266 EGFR ovary,NS,carcinoma,adenocarcinoma c.2165C>T p.A722V 7:55174024-55174024 4
30 COSM53224 EGFR ovary,NS,carcinoma,adenocarcinoma c.2173A>G p.T725A 7:55174032-55174032 4
31 COSM53213 EGFR ovary,NS,carcinoma,adenocarcinoma c.2604A>T p.E868D 7:55191853-55191853 4
32 COSM53229 EGFR ovary,NS,carcinoma,adenocarcinoma c.2232C>A p.I744I 7:55174769-55174769 4
33 COSM53231 EGFR ovary,NS,carcinoma,adenocarcinoma c.2559C>T p.I853I 7:55191808-55191808 4
34 COSM12373 EGFR ovary,NS,carcinoma,adenocarcinoma c.2159C>T p.S720F 7:55174018-55174018 4
35 COSM53265 EGFR ovary,NS,carcinoma,adenocarcinoma c.2556G>T p.K852N 7:55191805-55191805 4
36 COSM53235 EGFR ovary,NS,carcinoma,adenocarcinoma c.2481C>T p.Y827Y 7:55191730-55191730 4
37 COSM28286 EGFR ovary,NS,carcinoma,adenocarcinoma c.2494C>T p.R832C 7:55191743-55191743 4
38 COSM53228 EGFR ovary,NS,carcinoma,adenocarcinoma c.2123A>G p.K708R 7:55173982-55173982 4
39 COSM53227 EGFR ovary,NS,carcinoma,adenocarcinoma c.2506C>A p.R836S 7:55191755-55191755 4
40 COSM22499 ATM ovary,NS,carcinoma,adenocarcinoma c.1810C>T p.P604S 11:108252824-108252824 4
41 COSM6904304 AR ovary,NS,carcinoma,adenocarcinoma c.2179C>T p.R727C 23:67717483-67717483 4
42 COSM159008 AKT1 ovary,NS,carcinoma,adenocarcinoma c.235C>A p.Q79K 14:104776711-104776711 4
43 COSM1235014 U2AF1 cervix,NS,carcinoma,adenocarcinoma c.467G>A p.R156H 21:43094670-43094670 3
44 COSM10648 TP53 cervix,NS,carcinoma,adenocarcinoma c.524G>A p.R175H 17:7675088-7675088 3
45 COSM44399 TP53 cervix,NS,carcinoma,adenocarcinoma c.677G>T p.G226V 17:7674286-7674286 3
46 COSM10941 TP53 cervix,NS,carcinoma,adenocarcinoma c.730G>A p.G244S 17:7674233-7674233 3
47 COSM10725 TP53 cervix,NS,carcinoma,adenocarcinoma c.701A>G p.Y234C 17:7674262-7674262 3
48 COSM10662 TP53 cervix,NS,carcinoma,adenocarcinoma c.743G>A p.R248Q 17:7674220-7674220 3
49 COSM11333 TP53 cervix,NS,carcinoma,adenocarcinoma c.499C>T p.Q167* 17:7675113-7675113 3
50 COSM10656 TP53 cervix,NS,carcinoma,adenocarcinoma c.742C>T p.R248W 17:7674221-7674221 3
Sources

Expression for Carcinosarcoma

About this section
Search GEO for disease gene expression data for Carcinosarcoma.
Sources

Pathways for Carcinosarcoma

About this section

Pathways related to Carcinosarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 90)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 14.01 CTNNB1 ERBB2 HRAS KIT KRAS MME
2
ERK Signaling 64
Show member pathways
 13.84 CTNNB1 DES ERBB2 HRAS KIT KRAS
3
Developmental Biology 66
Show member pathways
 13.51 CTNNB1 ERBB2 HRAS KIT KRAS KRT7
4
Class I MHC mediated antigen processing and presentation 66
Show member pathways
 13.46 ERBB2 HRAS KIT KRAS PIK3CA PTEN
5
Cytokine Signaling in Immune system 66
Show member pathways
 13.36 ERBB2 HRAS KIT KRAS MUC1 PIK3CA
6
PAK Pathway 64
Show member pathways
 13.3 CTNNB1 ERBB2 HRAS KIT KRAS PTEN
7
Nanog in Mammalian ESC Pluripotency 64
Show member pathways
 13.28 CTNNB1 ERBB2 HRAS KIT KRAS VIM
8
Human cytomegalovirus infection 37
Show member pathways
 13.07 CTNNB1 HRAS KRAS PIK3CA PTEN TP53
9
TNFR1 Pathway 64
Show member pathways
 12.97 CTNNB1 HRAS KRAS PIK3CA PTEN TP53
10
PI3K-Akt signaling pathway 37
Show member pathways
 12.94 CTNNB1 ERBB2 HRAS KIT KRAS PIK3CA
11
Regulation of lipid metabolism Insulin signaling-generic cascades 22
Show member pathways
 12.92 ERBB2 HRAS KRAS PIK3CA PTEN
12
Focal Adhesion 1 37
Show member pathways
 12.91 CTNNB1 ERBB2 HRAS KRAS PIK3CA PTEN
13
NFAT and Cardiac Hypertrophy 64
Show member pathways
 12.88 ERBB2 HRAS KRAS PIK3CA PTEN
14
MAPK signaling pathway 37 1
12.79 ERBB2 HRAS KIT KRAS TP53
15
Glioma 37
Show member pathways
 12.79 ERBB2 HRAS KRAS PIK3CA PTEN TP53
16
Ras signaling pathway 37
Show member pathways
 12.75 CTNNB1 HRAS KIT KRAS PIK3CA
17
Endometrial cancer 37
Show member pathways
 12.72 CTNNB1 ERBB2 HRAS KIT KRAS PIK3CA
18
Downstream signaling events of B Cell Receptor (BCR) 66
Show member pathways
 12.71 ERBB2 HRAS KIT KRAS PIK3CA PTEN
19
Development Endothelin-1/EDNRA signaling 22
Show member pathways
 12.69 CTNNB1 HRAS KRAS PIK3CA PTEN
20
Development HGF signaling pathway 22
Show member pathways
 12.68 CTNNB1 ERBB2 HRAS KRAS PIK3CA PTEN
21
Pathways in cancer 37
12.64 CTNNB1 ERBB2 HRAS KIT KRAS PIK3CA
22
Immune response IL-23 signaling pathway 22
Show member pathways
 12.63 CTNNB1 ERBB2 HRAS KRAS PIK3CA TP53
23
Immune response Fc epsilon RI pathway 22
Show member pathways
 12.6 HRAS KRAS PIK3CA PTEN
24
Cytoskeletal Signaling 4
12.56 ACTC1 DES KRT7 MUC1 VIM
25
mTOR signaling pathway (KEGG) 65
Show member pathways
 12.54 ERBB2 HRAS KRAS PIK3CA PTEN TP53
26
Prolactin Signaling Pathway 1 37
Show member pathways
 12.51 ERBB2 HRAS KRAS PIK3CA PTEN
27
ErbB signaling pathway 1 37
Show member pathways
 12.5 ERBB2 HRAS KRAS PIK3CA TP53
28
Gastric cancer 37
Show member pathways
 12.48 CTNNB1 ERBB2 HRAS KIT KRAS PGR
29
Apoptosis Pathway 72
Show member pathways
 12.47 CTNNB1 ERBB2 HRAS KRAS PIK3CA TP53
30
Human T-cell leukemia virus 1 infection 37
12.46 CTNNB1 HRAS KRAS PIK3CA TP53
31
T cell receptor signaling pathway 37
Show member pathways
 12.45 HRAS KRAS PIK3CA VIM
32
Cushing syndrome 37
Show member pathways
 12.45 CTNNB1 HRAS KIT KRAS
33
Arrhythmogenic right ventricular cardiomyopathy (ARVC) 37
Show member pathways
 12.45 CTNNB1 DES HRAS KRAS
34
Phospholipase D signaling pathway 37
Show member pathways
 12.43 HRAS KIT KRAS PIK3CA
35
Development EGFR signaling pathway 22
Show member pathways
 12.43 CTNNB1 ERBB2 HRAS KRAS MUC1 PIK3CA
36
Development VEGF signaling via VEGFR2 - generic cascades 22
Show member pathways
 12.42 CTNNB1 HRAS KRAS PIK3CA
37
Development IGF-1 receptor signaling 22
Show member pathways
 12.42 HRAS PIK3CA PTEN TP53
38
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.42 CTNNB1 ERBB2 HRAS KIT KRAS PIK3CA
39
B cell receptor signaling pathway (KEGG) 37
Show member pathways
 12.4 HRAS KRAS PIK3CA PTEN
40
Signaling by ERBB2 66
Show member pathways
 12.35 ERBB2 HRAS KRAS PIK3CA
41
B Cell Receptor Signaling Pathway (sino) 67
Show member pathways
 12.35 HRAS KRAS PIK3CA PTEN
42
Viral carcinogenesis 37
12.32 HRAS KRAS PIK3CA TP53
43
MicroRNAs in cancer 37
12.28 ERBB2 HRAS KRAS PIK3CA PTEN TP53
44
Proteoglycans in cancer 37
12.26 CTNNB1 ERBB2 HRAS KRAS PIK3CA TP53
45
MAPK Signaling: Mitogen Stimulation Pathway 65
Show member pathways
 12.25 ERBB2 HRAS KRAS PIK3CA PTEN TP53
46
Cellular senescence (KEGG) 37
12.23 HRAS KRAS PIK3CA PTEN TP53
47
EGF/EGFR Signaling Pathway 1
12.22 ERBB2 HRAS KRAS PTEN
48
Kit receptor signaling pathway 1
Show member pathways
 12.21 HRAS KIT PIK3CA PTEN
49
mTOR Pathway 72
Show member pathways
 12.21 HRAS KRAS PIK3CA TP53
50
Development EGFR signaling via small GTPases 22
Show member pathways
 12.19 ERBB2 HRAS KRAS PIK3CA PTEN
Sources

GO Terms for Carcinosarcoma

About this section

Cellular components related to Carcinosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.73 ACTC1 CTNNB1 DES ERBB2 HRAS KRAS
2 focal adhesion GO:0005925 9.55 ACTC1 CTNNB1 KRAS MME VIM
3 cytoplasm GO:0005737 9.5 ACTC1 CTNNB1 DES ERBB2 HRAS KIT
4 fascia adherens GO:0005916 9.32 CTNNB1 DES
5 plasma membrane GO:0005886 10 CTNNB1 DES ERBB2 HRAS KIT KRAS

Biological processes related to Carcinosarcoma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.92 CTNNB1 HRAS KIT KRAS PTEN
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.81 ERBB2 HRAS KIT PTEN
3 cell proliferation GO:0008283 9.8 CTNNB1 ERBB2 HRAS PTEN TP53
4 phosphatidylinositol phosphorylation GO:0046854 9.76 ERBB2 KIT PIK3CA
5 MAPK cascade GO:0000165 9.76 ERBB2 HRAS KIT KRAS
6 positive regulation of DNA-binding transcription factor activity GO:0051091 9.75 CTNNB1 KIT PTEN
7 negative regulation of apoptotic process GO:0043066 9.73 ACTC1 CTNNB1 ERBB2 KIT PTEN TP53
8 Ras protein signal transduction GO:0007265 9.67 HRAS KRAS TP53
9 positive regulation of MAPK cascade GO:0043410 9.62 CTNNB1 ERBB2 HRAS KIT
10 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.61 HRAS KRAS MUC1
11 epithelial tube branching involved in lung morphogenesis GO:0060441 9.59 CTNNB1 KRAS
12 regulation of synaptic transmission, GABAergic GO:0032228 9.57 KRAS PTEN
13 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.56 MUC1 TP53
14 positive regulation of phospholipase C activity GO:0010863 9.55 HRAS KIT
15 replicative senescence GO:0090399 9.54 MME TP53
16 muscle filament sliding GO:0030049 9.54 ACTC1 DES VIM
17 response to isolation stress GO:0035900 9.48 HRAS KRAS
18 positive regulation of MAP kinase activity GO:0043406 9.46 ERBB2 HRAS KIT KRAS
19 cytokine-mediated signaling pathway GO:0019221 9.43 KIT KRAS MUC1 PIK3CA TP53 VIM
20 positive regulation of gene expression GO:0010628 9.28 ACTC1 CTNNB1 ERBB2 HRAS KIT KRAS

Molecular functions related to Carcinosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.8 DES ERBB2 PGR PTEN TP53 VIM
2 protein phosphatase binding GO:0019903 9.43 CTNNB1 ERBB2 TP53
3 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.13 ERBB2 KIT PIK3CA
4 protein C-terminus binding GO:0008022 8.92 CTNNB1 ERBB2 HRAS VIM
5 protein binding GO:0005515 10 CTNNB1 DES ERBB2 HRAS KIT KRAS
Sources

Sources for Carcinosarcoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....